The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Results of the PROMISE study of ~30,000 individuals screened for monoclonal gammopathies
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of the PROMISE study (NCT03689595), which screened approximately 30,000 high-risk individuals for monoclonal gammopathies. The study found a high prevalence of 14% in people of African descent, with age, sex, and family history of myeloma being strong predictive factors. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the PROMISE study is being presented here in the American Society of Hematology in 2025, and we’re very excited because it was truly a fruit of labor for many years, trying to recruit patients in the United States, but also we recruited in South Africa and Israel and Greece to look at patients who are at risk, meaning either family history of blood cancers or African-Americans or people of African descent...
So the PROMISE study is being presented here in the American Society of Hematology in 2025, and we’re very excited because it was truly a fruit of labor for many years, trying to recruit patients in the United States, but also we recruited in South Africa and Israel and Greece to look at patients who are at risk, meaning either family history of blood cancers or African-Americans or people of African descent. And we are now presenting 33,000 samples that we’ve looked at by mass spectrometry with a binding site to look at the level of monoclonal gammopathy of MGUS or higher, so MGUS or smoldering myeloma. And we indeed found very interestingly that an African-American population or people of African descent have a 14% prevalence, which is very high compared to what we’ve seen in Olmsted County. In those numbers, it was about 3% to 5%. So this is a much higher prevalence in people of African descent. We also saw that age, sex, which is male, more than female, as well as strong family history of myeloma in two family members is very strongly predictive of having MGUS or smoldering myeloma. We next use the ICE-TOP calculator, which is developed by the Icelandic group, to see if some of those patients will be at a higher level, almost to the level of smoldering multiple myeloma. And indeed, we find almost 2% of people of African descent will have a level of smoldering myeloma. These are the people that we are now considering for treatment, whether it’s lenalidomide or all of the other clinical trials that we’re developing right now. So it’s an exciting time for us to see we can detect early, especially people at risk, people of African descent and people with family history. And we know that we can identify in many ways genomics and CBC and immune who is at risk of developing myeloma, but we also have so many therapies that can prevent and intercept the disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
